94 related articles for article (PubMed ID: 19854350)
1. The function, proteolytic processing, and histopathology of Met in cancer.
Hanna JA; Bordeaux J; Rimm DL; Agarwal S
Adv Cancer Res; 2009; 103():1-23. PubMed ID: 19854350
[TBL] [Abstract][Full Text] [Related]
2. MET receptor tyrosine kinase as a therapeutic anticancer target.
Stellrecht CM; Gandhi V
Cancer Lett; 2009 Jul; 280(1):1-14. PubMed ID: 19100682
[TBL] [Abstract][Full Text] [Related]
3. Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer.
De Bacco F; Luraghi P; Medico E; Reato G; Girolami F; Perera T; Gabriele P; Comoglio PM; Boccaccio C
J Natl Cancer Inst; 2011 Apr; 103(8):645-61. PubMed ID: 21464397
[TBL] [Abstract][Full Text] [Related]
4. Met, the hepatocyte growth factor receptor, localizes to the nucleus in cells at low density.
Pozner-Moulis S; Pappas DJ; Rimm DL
Cancer Res; 2006 Aug; 66(16):7976-82. PubMed ID: 16912172
[TBL] [Abstract][Full Text] [Related]
5. RNA interference reveals that ligand-independent met activity is required for tumor cell signaling and survival.
Shinomiya N; Gao CF; Xie Q; Gustafson M; Waters DJ; Zhang YW; Vande Woude GF
Cancer Res; 2004 Nov; 64(21):7962-70. PubMed ID: 15520203
[TBL] [Abstract][Full Text] [Related]
6. Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival.
Lutterbach B; Zeng Q; Davis LJ; Hatch H; Hang G; Kohl NE; Gibbs JB; Pan BS
Cancer Res; 2007 Mar; 67(5):2081-8. PubMed ID: 17332337
[TBL] [Abstract][Full Text] [Related]
7. HGF/Met signalling promotes PGE(2) biogenesis via regulation of COX-2 and 15-PGDH expression in colorectal cancer cells.
Moore AE; Greenhough A; Roberts HR; Hicks DJ; Patsos HA; Williams AC; Paraskeva C
Carcinogenesis; 2009 Oct; 30(10):1796-804. PubMed ID: 19638428
[TBL] [Abstract][Full Text] [Related]
8. Structure, biosynthesis and biochemical properties of the HGF receptor in normal and malignant cells.
Comoglio PM
EXS; 1993; 65():131-65. PubMed ID: 8380735
[TBL] [Abstract][Full Text] [Related]
9. Hepatocyte growth factor enhances proteolysis and invasiveness of human nasopharyngeal cancer cells through activation of PI3K and JNK.
Zhou HY; Wan KF; Ip CK; Wong CK; Mak NK; Lo KW; Wong AS
FEBS Lett; 2008 Oct; 582(23-24):3415-22. PubMed ID: 18789327
[TBL] [Abstract][Full Text] [Related]
10. Hepatocyte growth factor induces Wnt-independent nuclear translocation of beta-catenin after Met-beta-catenin dissociation in hepatocytes.
Monga SP; Mars WM; Pediaditakis P; Bell A; Mulé K; Bowen WC; Wang X; Zarnegar R; Michalopoulos GK
Cancer Res; 2002 Apr; 62(7):2064-71. PubMed ID: 11929826
[TBL] [Abstract][Full Text] [Related]
11. From Tpr-Met to Met, tumorigenesis and tubes.
Peschard P; Park M
Oncogene; 2007 Feb; 26(9):1276-85. PubMed ID: 17322912
[TBL] [Abstract][Full Text] [Related]
12. Met receptor signaling: a key effector in esophageal adenocarcinoma.
Anderson MR; Harrison R; Atherfold PA; Campbell MJ; Darnton SJ; Obszynska J; Jankowski JA
Clin Cancer Res; 2006 Oct; 12(20 Pt 1):5936-43. PubMed ID: 17062664
[TBL] [Abstract][Full Text] [Related]
13. MicroRNAs impair MET-mediated invasive growth.
Migliore C; Petrelli A; Ghiso E; Corso S; Capparuccia L; Eramo A; Comoglio PM; Giordano S
Cancer Res; 2008 Dec; 68(24):10128-36. PubMed ID: 19074879
[TBL] [Abstract][Full Text] [Related]
14. Targeting MET as a strategy to overcome crosstalk-related resistance to EGFR inhibitors.
Karamouzis MV; Konstantinopoulos PA; Papavassiliou AG
Lancet Oncol; 2009 Jul; 10(7):709-17. PubMed ID: 19573800
[TBL] [Abstract][Full Text] [Related]
15. Genetic and expression analysis of MET, MACC1, and HGF in metastatic colorectal cancer: response to met inhibition in patient xenografts and pathologic correlations.
Galimi F; Torti D; Sassi F; Isella C; Corà D; Gastaldi S; Ribero D; Muratore A; Massucco P; Siatis D; Paraluppi G; Gonella F; Maione F; Pisacane A; David E; Torchio B; Risio M; Salizzoni M; Capussotti L; Perera T; Medico E; Di Renzo MF; Comoglio PM; Trusolino L; Bertotti A
Clin Cancer Res; 2011 May; 17(10):3146-56. PubMed ID: 21447729
[TBL] [Abstract][Full Text] [Related]
16. The Met pathway: master switch and drug target in cancer progression.
Mazzone M; Comoglio PM
FASEB J; 2006 Aug; 20(10):1611-21. PubMed ID: 16873884
[TBL] [Abstract][Full Text] [Related]
17. Drug development of MET inhibitors: targeting oncogene addiction and expedience.
Comoglio PM; Giordano S; Trusolino L
Nat Rev Drug Discov; 2008 Jun; 7(6):504-16. PubMed ID: 18511928
[TBL] [Abstract][Full Text] [Related]
18. Enhanced growth of human met-expressing xenografts in a new strain of immunocompromised mice transgenic for human hepatocyte growth factor/scatter factor.
Zhang YW; Su Y; Lanning N; Gustafson M; Shinomiya N; Zhao P; Cao B; Tsarfaty G; Wang LM; Hay R; Vande Woude GF
Oncogene; 2005 Jan; 24(1):101-6. PubMed ID: 15531925
[TBL] [Abstract][Full Text] [Related]
19. Profiling YB-1 target genes uncovers a new mechanism for MET receptor regulation in normal and malignant human mammary cells.
Finkbeiner MR; Astanehe A; To K; Fotovati A; Davies AH; Zhao Y; Jiang H; Stratford AL; Shadeo A; Boccaccio C; Comoglio P; Mertens PR; Eirew P; Raouf A; Eaves CJ; Dunn SE
Oncogene; 2009 Mar; 28(11):1421-31. PubMed ID: 19151767
[TBL] [Abstract][Full Text] [Related]
20. Novel therapeutic target for head and neck squamous cell carcinoma: HGF-MET signaling pathway.
Lau PC; Chan AT
Anticancer Drugs; 2011 Aug; 22(7):665-73. PubMed ID: 21709616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
